NEW YORK (GenomeWeb News) – Exact Sciences today said that it has filed the second module of a premarket approval application for its Cologuard colorectal cancer screening test with the US Food and Drug Administration.

The module, which was submitted to the agency on Friday, was comprised of the required studies and documentation establishing the analytical sensitivity and specificity, cross-reactivity, and other similar studies on the test. The firm said that the third and final module will include clinical data from its DeeP-C trial.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.